134 related articles for article (PubMed ID: 24107524)
1. [New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
Yoshisue H; Kozawa M; Hiratsuka M; Nakanishi M
Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):190-9. PubMed ID: 24107524
[No Abstract] [Full Text] [Related]
2. [Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
Ulrik CS
Ugeskr Laeger; 2013 Aug; 175(35):1946-8. PubMed ID: 23978116
[TBL] [Abstract][Full Text] [Related]
3. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
4. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
5. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M; D'Andrea P
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
[TBL] [Abstract][Full Text] [Related]
6. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Tashkin DP; Gross NJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():1873-1888. PubMed ID: 29928118
[TBL] [Abstract][Full Text] [Related]
7. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Bartels C; Looby M; Sechaud R; Kaiser G
Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
[TBL] [Abstract][Full Text] [Related]
8. Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate.
Ogoda M; Niiya R; Koshika T; Yamada S
J Pharmacol Sci; 2011; 115(3):374-82. PubMed ID: 21358117
[TBL] [Abstract][Full Text] [Related]
9. ▾Glycopyrronium for COPD.
Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
[TBL] [Abstract][Full Text] [Related]
10. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
Joos GF
Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
[TBL] [Abstract][Full Text] [Related]
11. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
12. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.
Casarosa P; Bouyssou T; Germeyer S; Schnapp A; Gantner F; Pieper M
J Pharmacol Exp Ther; 2009 Aug; 330(2):660-8. PubMed ID: 19478135
[TBL] [Abstract][Full Text] [Related]
14. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.
Montuschi P; Macagno F; Valente S; Fuso L
Curr Med Chem; 2013; 20(12):1464-76. PubMed ID: 22963553
[TBL] [Abstract][Full Text] [Related]
15. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
17. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
18. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
20. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
